bullish
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway
On December 16, 2024, Soligenix, Inc. (SNGX) announced it has opened patient enrollment for the confirmatory Phase 3 FLASH2 (Fluorescent Light...
What is covered in the Full Insight:
- Introduction to the FLASH2 Trial
- Comparison with the FLASH Trial
- Details on the Comparator Study
- Financial Overview of Soligenix
- Outlook and Valuation
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
x